Nordisk's top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study that may help boost sales of the injectable medicine. Victoza is only the second diabetes drug to show such heart benefits. John Buse, professor of medicine at the UNC School of Medicine, who worked on the study. said, "To me, the impressive thing about this trial is the consistency across clinical endpoints and its robustness." Because about half of deaths in people with diabetes are caused by heart disease, reducing heart risk is considered essential to their care.